Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.
作者信息
Renso Rossella, Aroldi Andrea, Pioltelli Pietro, Gambacorti-Passerini Carlo, Elli Elena Maria
机构信息
Hematology Division and Bone Marrow Unit, San Gerardo Hospital, Monza, Italy.
Department of Medicine, University of Milano-Bicocca, Monza, Italy.
出版信息
Blood Cancer J. 2018 Jun 11;8(6):56. doi: 10.1038/s41408-018-0091-6.
Abstract
摘要
Zotero 插件